Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Slides:

Advertisements

Similar presentations

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,

Advertisements

Figure 1 Proposed risk stratification for patients with NAFLD

Independent variables (baseline) Loge (HOMA-IR) b P

Copyright © 2017 American Academy of Pediatrics.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Figure 2 Inflammatory pathways affecting hepatic insulin resistance

Figure 2 Pathophysiology of hyperglycaemia in T2DM

with undiagnosed diabetes mellitus by three diagnostic criteria

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

How to Approach a Patient With Nonalcoholic Fatty Liver Disease

Figure 1 Pathophysiological aspects of insulin

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 5 Lipid droplet consumption

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 5 Risk factor control in the intensive treatment group

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Effects of irisin on glucose homeostasis

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Endocrinol. doi: /nrendo

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Impact of metabolic risk factors on HCC

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

HOMA calculations where glucose is mmol/L and insulin is mU/L

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Figure 2 Classifications and appearance of CCAs

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Homeostasis model assessment of insulin resistance (HOMA-IR) correlates strongly with serum adiponectin (ADPN), insulin-like growth factor I (IGF-I), and.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Homeostasis model assessment of insulin resistance (HOMA-IR) scores in obese women and obese women with gestational diabetes mellitus (GDM) at approximately.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Odds of incident diabetes by OGTT insulin patterns according to subjects characterized by presence or absence of IGT or dichotomized at the median value.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Figure 1. Schematic diagram of MR analysis to estimate expected association for genotypes (SNPs) with the trait of insulin resistance. The underlying assumption.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

How to Approach a Patient With Nonalcoholic Fatty Liver Disease

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients

Presentation transcript:

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus. These statements are in part based on the reported European NAFLD guidelines99,100. *Biomarkers have been well-studied to detect steatosis and fibrosis in NAFLD and have value in guiding clinical management. HbA1c, glycated haemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus. Tilg, H. et al. (2016) NAFLD and diabetes mellitus Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.147